Roger Song
Stock Analyst at Jefferies
(0.46)
# 3,158
Out of 4,667 analysts
38
Total ratings
20%
Success rate
-32.78%
Average return
Main Sectors:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Upgrades: Buy | $2 → $7 | $3.96 | +76.77% | 1 | Nov 19, 2024 | |
| IRON Disc Medicine | Initiates: Buy | $89 | $62.55 | +42.29% | 1 | Oct 23, 2024 | |
| BIOA BioAge Labs | Initiates: Buy | $42 | $18.40 | +128.26% | 1 | Oct 21, 2024 | |
| NVAX Novavax | Maintains: Buy | $31 → $25 | $8.06 | +210.17% | 2 | Oct 16, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $41 | $22.64 | +81.10% | 1 | Oct 11, 2024 | |
| ZBIO Zenas BioPharma | Initiates: Buy | $35 | $12.45 | +181.12% | 1 | Oct 8, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $40 | $21.21 | +88.59% | 1 | Sep 13, 2024 | |
| ATYR aTyr Pharma | Initiates: Buy | $9 | $2.99 | +201.00% | 1 | Sep 5, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $108 → $129 | $85.96 | +50.07% | 1 | Sep 3, 2024 | |
| CTMX CytomX Therapeutics | Upgrades: Buy | $2.5 → $8 | $0.87 | +819.43% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $91.17 | +6.39% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $72 | $24.00 | +200.00% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $51.53 | +113.47% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $0.5 → $1 | $1.00 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $61 → $55 | $9.77 | +463.24% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $8.05 | +334.78% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.96 | +835.84% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $15.91 | +119.99% | 1 | Feb 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $675 | $2.22 | +30,305.41% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $8.24 | -2.91% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3 → $4 | $0.33 | +1,112.12% | 2 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $315 | $0.39 | +81,085.57% | 1 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.67 | +686.52% | 1 | Sep 2, 2020 |
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.96
Upside: +76.77%
Disc Medicine
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $62.55
Upside: +42.29%
BioAge Labs
Oct 21, 2024
Initiates: Buy
Price Target: $42
Current: $18.40
Upside: +128.26%
Novavax
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $8.06
Upside: +210.17%
Nurix Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $22.64
Upside: +81.10%
Zenas BioPharma
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $12.45
Upside: +181.12%
Kiniksa Pharmaceuticals International,
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $21.21
Upside: +88.59%
aTyr Pharma
Sep 5, 2024
Initiates: Buy
Price Target: $9
Current: $2.99
Upside: +201.00%
Vaxcyte
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $85.96
Upside: +50.07%
CytomX Therapeutics
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $0.87
Upside: +819.43%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $91.17
Upside: +6.39%
Mar 20, 2024
Maintains: Buy
Price Target: $41 → $72
Current: $24.00
Upside: +200.00%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $51.53
Upside: +113.47%
Mar 6, 2024
Maintains: Hold
Price Target: $0.5 → $1
Current: $1.00
Upside: -
Nov 9, 2022
Assumes: Buy
Price Target: $61 → $55
Current: $9.77
Upside: +463.24%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $8.05
Upside: +334.78%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $0.96
Upside: +835.84%
Feb 15, 2022
Initiates: Buy
Price Target: $35
Current: $15.91
Upside: +119.99%
Jan 11, 2022
Initiates: Buy
Price Target: $675
Current: $2.22
Upside: +30,305.41%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $8.24
Upside: -2.91%
Nov 12, 2021
Upgrades: Buy
Price Target: $3 → $4
Current: $0.33
Upside: +1,112.12%
Sep 8, 2020
Initiates: Buy
Price Target: $315
Current: $0.39
Upside: +81,085.57%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $2.67
Upside: +686.52%